Riverside Partners Invests in Syner-G Pharma Consulting

Riverside Partners Combines Sequoia Biotech Consulting and Syner-G BioPharma Group

September 18, 2024

Healthcare Services

Boston-based private equity firm Riverside Partners has combined two of its portfolio companies, Sequoia Biotech Consulting and Syner-G BioPharma Group, into a single, integrated life‑sciences services business. The combined organization — bringing together regulatory, development, quality, and operational capabilities — has approximately 500 employees and will provide end-to-end solutions to pharmaceutical, biotechnology, and medical device clients.

Syner-G BioPharma Group (Riverside Partners) Acquires RMC Pharmaceutical Solutions

January 24, 2023

Healthcare Services

Syner-G BioPharma Group, a portfolio company of Riverside Partners, has acquired RMC Pharmaceutical Solutions, an outsourced CMC and quality management services provider based in Colorado. The add-on strengthens Syner-G's pharmaceutical science capabilities—particularly biologics and cell & gene therapy development—by integrating RMC's process and analytical development, regulatory strategy, and quality management expertise.

Syner-G Acquires Impact Pharmaceutical Services

February 1, 2022

Healthcare Services

Syner-G BioPharma Group, a portfolio company of Riverside Partners, has acquired Impact Pharmaceutical Services, a Research Triangle Park-based provider of medical writing, regulatory strategy, and regulatory publishing services for biotech and pharmaceutical clients. The deal, which closed in late December, expands Syner-G's CMC and regulatory capabilities to better support clients across pre-IND through post-marketing stages; financial terms were not disclosed.

Riverside Partners Completes Platform Investment in Sequoia Consulting Group

January 18, 2022

Healthcare Services

Riverside Partners, a Boston-based private equity firm, completed a platform investment in Sequoia Consulting Group, a San Diego–headquartered life sciences consulting firm led by founder and CEO Brandy Bullen. The partnership will support Sequoia’s growth, capability expansion, and geographic reach as the company continues to provide technical operations, quality and scientific operations, business transformation, and program/project management services to biotech, pharma, diagnostics, and medical device clients.

GHO Capital and Partners Group Invest in Sterling Pharma Solutions

May 25, 2023

Pharmaceuticals

GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.

Symeres Acquires DGr Pharma

September 15, 2025

Healthcare Services

Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.